Why Pfizer Stock Is a Surefire Winner in 2022
Pharmaceutical giant Pfizer (NYSE: PFE) has been at the front of the industry, developing treatments for COVID since the pandemic started. While it's unfortunate that the world continues to grapple with various strains of the virus, most recently the omicron variant, Pfizer's products remain in high demand, which will likely boost its 2022 business results.
Below we will put some numbers to just how much Pfizer's treatments boosted its business this year and why 2022 could continue the trend, making it a surefire winning stock this year.
It's been about a year since the first COVID vaccines were made available in the United States, and the race has been on to ramp up the production and distribution of doses. Several companies worked to develop vaccines, but it has become a two-company market. The vast majority of doses administered in the U.S. have come from Pfizer and Moderna, two companies that developed the vaccines using mRNA technology.
Source Fool.com
